HEMABATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hemabate, and what generic alternatives are available?
Hemabate is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in HEMABATE is carboprost tromethamine. There is one drug master file entry for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the carboprost tromethamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hemabate
A generic version of HEMABATE was approved as carboprost tromethamine by DR REDDYS on July 2nd, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HEMABATE?
- What are the global sales for HEMABATE?
- What is Average Wholesale Price for HEMABATE?
Summary for HEMABATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 40 |
| Clinical Trials: | 6 |
| Patent Applications: | 228 |
| Drug Prices: | Drug price information for HEMABATE |
| What excipients (inactive ingredients) are in HEMABATE? | HEMABATE excipients list |
| DailyMed Link: | HEMABATE at DailyMed |
Recent Clinical Trials for HEMABATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Northwestern University | Early Phase 1 |
| West China Second University Hospital | Phase 4 |
| Huadu District People's Hospital of Guangzhou | N/A |
Pharmacology for HEMABATE
| Drug Class | Prostaglandin Analog |
US Patents and Regulatory Information for HEMABATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | HEMABATE | carboprost tromethamine | INJECTABLE;INJECTION | 017989-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HEMABATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | HEMABATE | carboprost tromethamine | INJECTABLE;INJECTION | 017989-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for HEMABATE
See the table below for patents covering HEMABATE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 81615 | ⤷ Sign Up | |
| Norway | 136250 | ⤷ Sign Up | |
| Sweden | 388852 | 15-METYL- OCH 15-ETYLPROSTAGLANDINFORENINGAR AVSEDDA ATT ANVENDAS SOM ANTIFERTILITETSMEDEL OCH SETT ATT FRAMSTELLA DESSA FORENINGAR AV TYP PGF | ⤷ Sign Up |
| Japan | S5217449 | PROCESS FOR MANUFACTURE OF 155ALKYLPROSTAGLANDIN | ⤷ Sign Up |
| Israel | 45415 | 5-ALKYL-15(R)-PROSTAGLANDINS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
